...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Canadian Journal of Neurological Sciences: le Journal Canadien des Sciences Neurologiques >PCV for oligodendroglial tumors: in search of prognostic factors for response and survival.
【24h】

PCV for oligodendroglial tumors: in search of prognostic factors for response and survival.

机译：PCV用于少突神经胶质瘤：寻找反应和生存的预后因素。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: We report survival and pretreatment prognostic factors for survival and chemosensitivity in 53 oligodendrogliomas treated with PCV (procarbazine, lomustine and vincristine) chemotherapy. METHODS: A total of 53 patients with histologically proven oligodendroglioma, anaplastic oligodendroglioma or oligo-astrocytoma and treated with PCV were extracted from the London Regional Cancer Center database. A retrospective review was conducted to evaluate overall survival and pretreatment prognostic factors for survival and chemosensitivity. RESULTS: The median survival time from diagnosis was 123.6 months. The overall five- and ten-year survival rates were 72.7% and 52.7% respectively. Age <40, seizure as an initial symptom, absence of cognitive deficit and presence of a homogeneous hypodense lesion without contrast enhancement on the initial pretreatment CT scan were all factors independently associated with favorable outcome. The presence of increased cellularity, pleomorphism, mitosis, vascular proliferation and grading as an anaplastic lesion using these surrogates on pathological assessment, were all associated with an unfavorable outcome in univariable analysis. In multivariable analysis, only the anaplastic grading and presence of increased cellularity were significant determinants of unfavorable survival. The only factor adversely associated with chemosensitivity was the presence of a focal symptom at presentation. CONCLUSION: Overall survival is significantly longer in oligodendroglial lesions than in fibrillary astrocytic tumors. A two tier grading system using standard morphological features seems accurate in predicting outcome in these patients. The presence of a neoplastic astrocytic component does not seem to impact the outcome. No clinical, radiological or pathological factor could be identified to reliably predict chemotherapy response.
机译：背景：我们报道了53例接受PCV（丙卡巴嗪，洛莫司汀和长春新碱）化疗的少突胶质细胞瘤的生存率和化学敏感性的生存率和预处理预后因素。方法：从伦敦地区癌症中心数据库中提取53例经组织学证实的少突胶质细胞瘤，间变性少突胶质细胞瘤或少星形胶质细胞瘤的患者。进行了回顾性评估，以评估总体生存率和生存期和化学敏感性的预处理预后因素。结果：从诊断得出的中位生存时间为123.6个月。五年和十年的总体生存率分别为72.7％和52.7％。年龄<40岁，癫痫发作为初始症状，缺乏认知缺陷以及在治疗前的CT扫描中均未出现对比增强的均质低密度病变均与预后良好相关。使用这些替代物进行病理评估时，细胞增多，多态性，有丝分裂，有丝分裂，血管增生和间变性病变的分级存在，均与单因素分析的不良结果相关。在多变量分析中，仅变性的分级和细胞增多的存在是不良存活的重要决定因素。与化学敏感性相反的唯一因素是出现局灶性症状。结论：少突胶质细胞病变的总生存期明显长于纤维性星形细胞肿瘤。使用标准形态特征的两级评分系统似乎可以准确预测这些患者的预后。肿瘤性星形细胞成分的存在似乎并不影响结果。没有临床，放射学或病理学因素能够可靠地预测化疗反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号